PMID- 35313793
OWN - NLM
STAT- MEDLINE
DCOM- 20220404
LR  - 20221207
IS  - 1464-5157 (Electronic)
IS  - 0265-6736 (Linking)
VI  - 39
IP  - 1
DP  - 2022
TI  - Effectiveness and immune responses of focused ultrasound ablation for cervical 
      intraepithelial neoplasia.
PG  - 539-546
LID - 10.1080/02656736.2022.2052365 [doi]
AB  - PURPOSE: To investigate the safety, efficacy, and the immune responses of focused 
      ultrasound in cervical intraepithelial neoplasia (CIN). METHODS: Patients with 
      biopsy-confirmed CIN were recruited for focused ultrasound treatment and asked to 
      return during 3-6 and 6-12 months post-treatment to receive cervical cytology, 
      high-risk human papilloma virus (HPV) detection, and colposcopy. The effective 
      rate was evaluated within 3-6 months, whereas the recurrence rate was evaluated 
      within 6-12 months. Cervicovaginal lavage and cervical tissue were sampled before 
      and 3-6 months after treatment. The expression of interferon gamma (IFN-gamma), 
      endoplasmic reticulum aminopeptidase 1 (ERAP1), human leucocyte antigen I 
      (HLA-I), cluster of differentiation 4 (CD4), and cluster of differentiation 8 
      (CD8) in the cervical tissue were observed by immunohistochemistry. 
      Immunoglobulin A (IgA) and interleukin 10 (IL-10) levels in the cervicovaginal 
      lavage were detected by enzyme-linked immunosorbent assay. Comparisons were made 
      in immune analyte levels before and after treatment. RESULTS: We analyzed the 
      results of 154 patients. The effective rate at 3-6 months was 96.8%. The 
      recurrence rate at 6-12 months was 2.0%. The eradication rate of HPV was 72.4% at 
      3-6 months and 81.0% at 6-12 months. No serious adverse reactions and 
      complications were observed. After treatment, a higher expression of ERAP1 was 
      observed (p < 0.05). Significant down-regulation of IgA and IL-10 were detected 
      (each p < 0.05). However, the expression of CD4, CD8, HLA-I, as well as the 
      release of IFN-gamma, did not reach statistical significance (each p > 0.05). 
      CONCLUSIONS: Focused ultrasound is an effective and safe therapy for treating 
      CIN, which could improve the local immune milieu of the cervix to some extent.
FAU - Zeng, Hongmin
AU  - Zeng H
AD  - Department of Obstetrics and Gynecology, The Second Affiliated Hospital of 
      Chongqing Medical University, Chongqing, People's Republic of China.
FAU - Liu, Maoyu
AU  - Liu M
AD  - Department of Obstetrics and Gynecology, The Second Affiliated Hospital of 
      Chongqing Medical University, Chongqing, People's Republic of China.
FAU - Xiao, Linlin
AU  - Xiao L
AD  - Department of Obstetrics and Gynecology, The Second Affiliated Hospital of 
      Chongqing Medical University, Chongqing, People's Republic of China.
FAU - Zhang, Xiaoyuan
AU  - Zhang X
AD  - Department of Obstetrics and Gynecology, The Second Affiliated Hospital of 
      Chongqing Medical University, Chongqing, People's Republic of China.
FAU - Feng, Qing
AU  - Feng Q
AD  - Department of Obstetrics and Gynecology, The Second Affiliated Hospital of 
      Chongqing Medical University, Chongqing, People's Republic of China.
FAU - Chang, Shufang
AU  - Chang S
AUID- ORCID: 0000-0001-5836-733X
AD  - Department of Obstetrics and Gynecology, The Second Affiliated Hospital of 
      Chongqing Medical University, Chongqing, People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Int J Hyperthermia
JT  - International journal of hyperthermia : the official journal of European Society 
      for Hyperthermic Oncology, North American Hyperthermia Group
JID - 8508395
RN  - 0 (Minor Histocompatibility Antigens)
RN  - 82115-62-6 (Interferon-gamma)
RN  - EC 3.4.11.- (Aminopeptidases)
RN  - EC 3.4.11.- (ERAP1 protein, human)
SB  - IM
MH  - Aminopeptidases
MH  - Female
MH  - *High-Intensity Focused Ultrasound Ablation
MH  - Humans
MH  - Immunity
MH  - Interferon-gamma
MH  - Minor Histocompatibility Antigens
MH  - *Uterine Cervical Neoplasms/immunology/surgery
MH  - *Uterine Cervical Dysplasia/immunology/surgery
OTO - NOTNLM
OT  - FUS
OT  - HPV
OT  - cervical intraepithelial neoplasia
OT  - effectiveness
OT  - immune
EDAT- 2022/03/23 06:00
MHDA- 2022/04/05 06:00
CRDT- 2022/03/22 05:30
PHST- 2022/03/22 05:30 [entrez]
PHST- 2022/03/23 06:00 [pubmed]
PHST- 2022/04/05 06:00 [medline]
AID - 10.1080/02656736.2022.2052365 [doi]
PST - ppublish
SO  - Int J Hyperthermia. 2022;39(1):539-546. doi: 10.1080/02656736.2022.2052365.